CHMP recommends extending indication of Ruconest to children with Hereditary Angioedema.- Pharming
Related news and insights
BioCryst Pharmaceuticals announced new long-term efficacy and safety data from the APeX-2 and APeX-S clinical trials evaluating oral, once-daily Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) showing sustained reductions in attack rates and improvement in quality of life (QoL) among patients living with HAE, and improved management of symptoms after switching to Orladeyo from an injectable long-term prophylactic treatment (LTP).
BioCryst Pharmaceuticals, Inc. announced that Health Canada has approved oral, once-daily Orladeyo (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
Takeda announced that the Phase III SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of Takhzyro (lanadelumab) in patients 2 to <12 years of age in preventing hereditary angioedema (hae) attacks is complete and has met its objectives.